<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287338</url>
  </required_header>
  <id_info>
    <org_study_id>PP0 AC 01</org_study_id>
    <secondary_id>141741</secondary_id>
    <nct_id>NCT01287338</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.</brief_title>
  <official_title>A Randomized, Double-Masked, Placebo-Controlled, Proof of Concept Study to Evaluate the Short-term Safety and Efficacy of the QLT Proprietary Olopatadine Punctal Plug Delivery System in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mati Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test if olopatadine punctal plugs can reduce the symptoms
      (itching) of allergic conjunctivitis to ragweed in an Environmental Exposure Chamber model.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of definitive clinical results.
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of olopatadine-PPDS in subjects with seasonal allergic conjunctivitis to ragweed</measure>
    <time_frame>4 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in subject-rated ocular itching scores in treated vs placebo control arms in subjects with seasonal allergic conjunctivitis to ragweed</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline and observed values in subject rated ocular itching scores compared between lower puncta delivery and double puncta delivery arms</measure>
    <time_frame>4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Seasonal Allergic Conjunctivitis to Ragweed</condition>
  <arm_group>
    <arm_group_label>Lower Puncta Delivery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Puncta Delivery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine</intervention_name>
    <description>low dose</description>
    <arm_group_label>Lower Puncta Delivery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine</intervention_name>
    <description>high dose</description>
    <arm_group_label>Double Puncta Delivery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of allergic conjunctivitis to ragweed for at least one year

          -  Positive skin prick test to ragweed pollen within 12 months prior to visit 1

          -  BCVA of at leat 20/400

        Exclusion Criteria:

          -  Structural lid abnormalities (ectropion, entropion)

          -  Active lid disease ( ie moderate or severe blepharitis, meibomianitis) that requires
             medical treatment

          -  Presence of follicular conjunctivitis, anterior uveitis or preauricular
             lymphadenopathy

          -  History of ophthalmic abnormality, including a history of dry eye

          -  Perennial allergic rhinoconjunctivitis having significant allergy to animal dander
             that cannot be avoided during the study period

          -  History of chronic bacterial or viral ocular infection, such as herpes keratitis,
             and/or presence of active bacterial or viral ocular infection

          -  presence of mucous discharge, excess lacrimation or burning as a symptoms of ocular
             disease

          -  Currently on any chronic ocular topical medications

          -  Use of topical or systemic ocular medications during the study period

          -  History of complications, adverse events, trauma or disease in the nasolacrimal area

          -  History of symptomatic epiphoria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dipak Panigrahi, MD</last_name>
    <role>Study Director</role>
    <affiliation>QLT Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deepen Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2011</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

